Core Insights - Viatris Inc. (NASDAQ: VTRS) is recognized as one of the 13 Best March Dividend Stocks to Buy [1] - UBS has raised its price target for Viatris from $18 to $20, maintaining a Buy rating, citing the company's achievement of Q4 cost-saving goals and positive FY26 guidance [2] - The company reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for Q4 2025, indicating strong financial performance [3] Financial Performance - Viatris achieved total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion in Q4 2025, reflecting the overall strength of the business [3] - The company returned over $1 billion to shareholders through dividends and share repurchases during the year [4] Growth Outlook - Viatris expects to generate approximately $650 million in gross cost savings over three years, with up to $250 million reinvested into growth initiatives [5] - The company is preparing for a potential FDA reinspection of its Indore facility, implementing operational redundancies to ensure continuity and stability [5] Pipeline Progress - Five Phase III studies have delivered positive results, marking an important milestone for the company [4] - Enrollment in key programs, including cenerimod and selatogrel, is progressing and expected to be completed in 2026 [4] Strategic Initiatives - The completion of 60 regional transactions, including the acquisition of Aculys Pharma in Japan, is part of Viatris' broader strategic plan [4]

You can find original article here Nrn. Subscribe to our free daily Nrn newsletters. Papa Johns has announced several cost savings and financial improvement measures for 2026 and beyond, including 300 closures of underperforming stores by 2027 (with 200 closing this year), and 7% corporate layoffs.  The pizza chain is now in year two of its transformation plan under CEO Todd Penegor and is looking to balance cost savings with “recruiting new customers to the brand,” Penegor said during Thursday’s Q ...

Papa John’s International (NasdaqGS:PZZA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsHeather Hollander - SVP, Finance and Corporate ControllerRavi Thanawala - CFO and President, North AmericaTodd Penegor - President and CEOConference Call ParticipantsBrian Bittner - Managing Director and Senior AnalystIsiah Austin - Equity Research AnalystJim Sanderson - Managing Director and Research AnalystTodd Brooks - Equity Research AnalystOperatorHello. Thank you for standing by. Welcome t ...

Papa John’s International (NasdaqGS:PZZA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker4Hello. Thank you for standing by. Welcome to Papa John's fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask the question during the session, you will need to press star one one on your telephone. You would hear an automated message advising your hand is rai ...

Q4 & Full Year 2025 Earnings February 26, 2026 © 2026 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about: 2026 financial guidance; enterprise-wide strategic review ...

Core Insights - Viatris reported strong financial results for Q4 and full year 2025, with total revenues of $3.7 billion for Q4 and $14.3 billion for the full year, meeting or exceeding financial guidance across all key metrics [1][2][3] - The company completed an enterprise-wide strategic review, expecting to deliver $650 million in total cost savings while reinvesting up to $250 million over the next three years [1][3] - Viatris anticipates regulatory decisions for six product candidates in 2026 and multiple important pipeline milestones, positioning itself for sustainable growth [1][3] Financial Performance - Q4 2025 total revenues increased by 5% compared to Q4 2024, while full year revenues decreased by 3% compared to 2024 [2][3] - U.S. GAAP net loss for Q4 2025 was $340.1 million, a 34% improvement from a loss of $516.5 million in Q4 2024 [2][3] - Adjusted net earnings for Q4 2025 were $658.7 million, with adjusted EPS of $0.57, reflecting a 6% increase from Q4 2024 [2][3] Strategic Initiatives - The company initiated restructuring activities as part of its strategic review, expecting a global workforce reduction of up to 10% [3][6] - Total pre-tax charges related to restructuring are estimated between $700 million and $850 million, with anticipated savings of $600 million to $700 million once fully implemented [3][6] - Viatris plans to provide a balanced capital allocation approach for 2026, returning over $1 billion to shareholders in 2025 [1][3] Product Pipeline and Regulatory Updates - The company generated approximately $78 million in new product revenues in Q4 2025, with expectations of $450 million to $550 million in new product revenues for 2026 [2][3] - Viatris has several regulatory submissions under review, including a J-NDA for pitolisant in Japan and an NDA for a low-dose estrogen weekly patch in the U.S. [2][6] - The FDA has assigned a PDUFA goal date of July 30, 2026, for the low-dose estrogen patch and October 17, 2026, for MR-141 [6] Market Performance - Generics net sales were impacted by competition in North America and government price regulations in Japan, while brands net sales showed strength in Greater China and Emerging Markets [2][3] - The company expects continued operational growth driven by its base business and net cost savings in 2026 [1][3]

Energy Recovery (NasdaqGS:ERII) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsDavid Moon - President and CEOJoshua Ballard - CFOLarry Solow - Managing DirectorNone - Company RepresentativeConference Call ParticipantsJeffrey Campbell - Senior AnalystSandhya Iyer - Research AnalystOperatorGood day, ladies and gentlemen, and welcome to Energy Recovery's fourth quarter and full year 2025 earnings call. During today's call, Energy Recovery may make projections and other forward-looking ...

This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Dive Brief: Electric vehicle manufacturer Lucid Motors is slashing its U.S. workforce by about 12%, excluding hourly production workers in manufacturing, logistics and quality, the company said Tuesday. The plan was launched to reallocate resources following the launch of Gravity, the company’s first SUV model, and to support a new phase of discipline and “margin progress ...

PresentationGood morning, and welcome to the Diageo interim results presentation. As you know, it's my first results session for Diageo. In fact, this is my seventh week, and I'll share a few initial impressions and immediate priorities with you later. But first, I'd like to hand over to Nik to share with you the results of the first half of 2026. Nik?Manik JhangianiCFO & Director Thank you, Dave, and welcome to Diageo. In the context of a continued challenging macro environment and industry backdrop in man ...

Realigned the field-based biomedical technician team to focus on smaller, more profitable client engagements rather than high-volume, low-return contracts.Strengthened the balance sheet by reducing net debt by 30% year-over-year while simultaneously returning capital through the repurchase of 1.3 million shares.Achieved a record quarterly adjusted EBITDA margin of 24.3%, driven by improved labor efficiency in biomedical services and a favorable shift toward higher-margin oncology revenue.Restructured the co ...